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Since the genome-wide association studies in Alzheimer’s disease have highlighted inflammation as a driver of the
disease rather than a consequence of the ongoing neurodegeneration, numerous studies have been performed to
identify specific immune profiles associated with healthy, ageing, or diseased brain. However, these studies have
been performed mainly in in vitro or animal models, which recapitulate only some aspects of the pathophysiology
of human Alzheimer’s disease. In this review, we discuss the availability of human post-mortem tissue through brain
banks, the limitations associated with its use, the technical tools available, and the neuroimmune aspects to explore
in order to validate in the human brain the experimental observations arising from animal models.Introduction
The concept of research on human samples has been
pioneered by neuropathologists who had an interest in
research and who started to archive brain specimens re-
ferred for diagnosis, such as the one developed by John
Corsellis in 1950 [1]. Development of novel technologies
to detect biological molecules and increased collaboration
with scientists highlights the need for the use of human
samples, especially in the neurosciences. Indeed, one of
the major limitations to our knowledge of human neuro-
logical diseases resides partly in the limits inherent to
animal models, which mimic some aspects of the human
neurological disorder without reproducing its complexity
arising from both genetic and environmental factors. For
example, more than 50 different animal models have
been generated to explore Alzheimer’s disease (AD) [2]
and more than 20 models are available for the study of
schizophrenia [3] without clear consensus about the
similarities with human disease. The underuse of post-
mortem human brain tissue also impedes the deeper
understanding of the pathophysiological processes on-
going in the diseased brain [3].
Therefore, in the mid-20th century, the notion of brain
banking to archive, collect, and use human brain samples
became essential with the aim to facilitate access to the* Correspondence: d.boche@soton.ac.uk
2Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of
Medicine, University of Southampton, Southampton General Hospital,
Tremona Road, Southampton SO16 6YD, UK
Full list of author information is available at the end of the article
© 2015 Gomez-Nicola and Boche; licensee Bio
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.tissue, to simplify the administrative burden for the re-
searcher, and to improve their quality for cutting-edge
research on neurological diseases. In this review, we dis-
cuss the pros and cons related to the use of human tissue,
the parameters susceptible to influence the neuroinflam-
matory changes, and how to analyse them in AD.
Requirements and limitations to the use of post-
mortem brain tissue
Ethics
Networks of brain tissue banks have been created to allow
request of tissue through a unique portal such as the con-
sortium BrainNet Europe in 2001 under the European
Commission or the UK Network of Brain Tissue Banks in
2009 by the Medical Research Council. In the UK, the
use of human tissue is regulated by the Human Tissue
Authority (HTA) and brain banks are licensed to operate
as research tissue banks by the HTA under ethical ap-
proval provided by an ethics committee. This implies that
the use of human tissue for a specific project is subject to
approval by the brain bank committee. This is a compul-
sory step that could hinder the researcher and thus might
appear as a limitation. However, under the approval of the
brain bank, the study is ethically covered by the bank,
saving administrative burden to the researcher and thus
optimising the time spent on the project. This procedure
is not restricted to the UK; the same principle applies
worldwide [4]. Information about US brain banks is found
under the platform National Institutes of Health Neuro-
BioBank. The Australian Brain Bank Network, in additionMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Gomez-Nicola and Boche Alzheimer's Research & Therapy  (2015) 7:42 Page 2 of 8to provide tissue for research, offers a neuropathology
diagnostic service and education and training oppor-
tunities. Asia has started to set up brain banks in Japan,
India, and China. Two brain banks are also present in
South America: one in Brazil (the Brain Bank of the
Brazilian Aging Brain Study Group, Sao Paulo) and one
in Argentina.
Quality of the tissue
Quality of the tissue during its acquisition and long-term
preservation is the principal objective of the bank. Differ-
ent parameters may impact on the integrity of the tissue
and thus on any biological molecules. Therefore, it is im-
portant to take into account these factors in the analysis
of inflammatory events. These include age (the immune
profile is known to evolve with ageing [5]), gender, genetic
heterogeneity, agonal status (defined as the deep infre-
quent respiration in the final moments before death),
preterminal medication, cause of death, concomitant dis-
ease, post-mortem interval [6], and time in the fixative. In
addition, the potential role of systemic inflammatory
diseases and infections may influence the cerebral in-
flammatory status [7]. Clinical studies have reported an
accelerated deterioration of the cognition in the AD pa-
tients affected by systemic infections [8,9], and experi-
mental studies demonstrated that systemic infection can
switch the brain inflammation to a more aggressive pheno-
type, resulting in increased neurodegeneration [10,11].
It is usual practise in most of the prospective brain
banks to fix one hemisphere and freeze the other hemi-
sphere when collecting tissue. The preparation of the fixed
tissue is a routine procedure used for diagnosis in any
pathology department and thus a standardised protocol
among the brain banks. Fixed tissue is used for histo-
logical staining and protein detection by immunohisto-
chemistry, and the main difficulty is to achieve optimal
specificity of the staining. Indeed, optimisation of the
staining might require testing antibodies from different
companies, using several pre-treatments (that is, antigen
retrieval), and importantly ensuring that the detected
staining is specific. This could be tested by using sam-
ples from another organ that expresses the protein of
interest (such as the lymph node for any macrophage/
microglia proteins) or by a blocking experiment to test
the specificity of the primary antibody or by doing both
[12]. The preparation of fresh frozen tissue is more chal-
lenging as genetic material is susceptible to degradation
under the factors described above and sometimes is not
available from the archives of tissue banks. In addition,
the development of genomic and proteomic technologies
has highlighted the importance of obtaining high-quality
RNA. If available, brain tissue pH and RIN (RNA integrity
number) value are proxy indices of agonal status [13] and
thus good indicators of the quality of the frozen tissue asfar as the preservation of RNA and proteins is concerned
[14]. Proteins are known to be more resistant as they can
still be detected in tissue even when RNA is degraded
[14]. Overall, standardized protocols have been developed
and optimized by brain banks to minimize the impacts of
pre- and post-mortem conditions.
Information required for the analysis of the
immune response in Alzheimer’s disease
To ensure that the detection of the inflammatory profile
is optimal in the human samples, the study should be
adequately designed to overcome or minimize the impact
of the factors discussed above. This can be achieved by
the following:
 Age and gender: to match selected cases.
 Genetic heterogeneity: to determine the sample size
necessary to reach statistical power [15].
 Agonal status: to obtain pH and RIN values. The RIN
algorithm has been designed to provide unambiguous
assessment of RNA integrity based on a numbering
system from 1 to 10, with 1 being the most degraded
profile and 10 being the most intact [13]. The choice
of the RIN value will depend on the technique to be
used, as microarray analysis will need a higher RIN
value than RT-PCR [14].
 Pre-terminal medication or concomitant disease or
both: to get access to the post-mortem report and to
control the quantitative analysis for these confounding
factors.
 Cause of death: to refer to the death certificate.
 Post-mortem interval: to select cases with the shortest
interval and usually no more than 72 hours.
 Time in the fixative: to ensure that sections are
provided from blocks taken at the post-mortem
examination after a standardised time in the fixative.
Overall, the experimental group should be matched as
closely as possible with the controls and the case selec-
tion based on the question investigated. The quantitative
findings should be controlled for the influences of any
pre- or post-mortem factors or both. Access to detailed
clinical records is becoming an important point for the
analysis of any quantitative assessment, information which
might not be available or which might be incomplete
because of the age of the case.
Other factors to account for the analysis are the known
genetic risk factors. The polymorphism of the apolipopro-
tein E (APOE) gene is the major risk factor for sporadic
AD [16], a fact recently reiterated in a number of genome-
wide association studies (GWASs) [17,18]. In the context
of inflammation in AD, this is an important point to con-
sider in the constitution of the cohort to study as APOE
genotype has been associated with microglial activation
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[19] and in the microglial expression of inflammatory
molecules [20].
How to analyse the neuroinflammatory response
As mentioned above, different types of tissue are available
from brain banks, and the most common are fixed paraffin-
embedded and frozen tissue. Fixed paraffin-embedded
tissue will be useful to perform immunohistochemical
detection of markers of interest. Brain sections could
be used at a range of thickness (4 to 30 μm), depending
on the experimental needs. The use of thick sections
(20 to 30 μm) combined with free-floating immunohis-
tochemistry is highly encouraged (sometimes available
if fixed tissue is not paraffin-embedded), as it facilitates
the permeation of the antibodies and provides a more
effective removal of background staining. Glass-mounted
thin sections (4 to 10 μm) can also give good results pro-
vided that appropriate protocol optimization is performed.
Neuroinflammation can be analyzed in fixed tissue in dif-
ferent but complementary approaches: the qualitative or
quantitative assessment or both. Qualitative assessment
relies on description according to set criteria and thus can
be interpreted as a subjective assessment. Qualitative
assessment to be obtained on tissue is (i) the presence
or absence of the marker of interest, (ii) the type of cell
or feature recognized by the marker, and (iii) the cell
morphology (for example, amoeboid, ramified, or dys-
trophic). However, it is now recognized that morphology
is not sufficient to reflect the multitude of functions or ac-
tivation states expressed by microglia [21]. Therefore, the
quantitative approach is essential to obtain an objective
measurement of the different markers studied. Quantifica-
tion relies on sampling and statistical analysis based on
numerical data collected. A semi-quantitative analysis can
be performed on the basis of a rating system such as a
scale of severity/intensity of the marker of interest, defined
according to the pattern of immunostaining (for example,
0, 1+, 2+, and 3+) and usually assessed blindly by at least
two researchers. Quantitative assessment can be obtained
as (i) the number of positive cells per field or per area/
volume unit, (ii) the protein load defined as the percentage
of the immunostained area of region sampled, and thus
(iii) the protein load per cell. For example, Iba1 (ionized
calcium-binding adaptor molecule 1) is currently ac-
knowledged as being expressed independently of micro-
glial functional state [22], and its expression is increased
during neuroinflammation. Detection of Iba1 is widely
used in animal studies, and Iba1 is the reference marker
for microglial assessment in the human brain [23]. The
numerical data collected are important for statistical
power, and collection can be achieved in different ways:
(i) by having sufficient cases in each group, (ii) by asses-
sing several brain areas if there are not enough cases, (iii)by collecting enough individual data within each case, or
(iv) by doing a combination of these.
The use of frozen tissue will allow the study of gene
expression (for example, RT-PCR and microarrays) and
protein expression (such as multiplex assays and Western
blotting). The RNA or protein isolation methods should
match the requirements of the techniques to be applied,
and sample size, RNA species, and purity are the main
variables to take into account. Owing to the intrinsic value
of the human samples, it is highly encouraged when ana-
lyzing RNA expression to use isolation kits allowing the
purification of all species of RNA, including microRNA,
which will allow the multiple analysis. As mentioned
previously, quality of frozen tissue is one challenge of
post-mortem brain; thus, in addition to the parameters
described above, adequate experimental controls are
essential for the data analysis.
Microglia, as the brain macrophages, have the property
to express a range of inflammatory markers [21,24-28].
If the considerations described above are taken into ac-
count, functional immune changes can be assessed in the
human brain by using specific markers as detailed below.
Inflammatory profile
Despite a broad interest in the inflammatory response in
AD and the extensive research in this disease, the scien-
tific community has failed to shed clear and uniform light
on the contribution of local inflammation to the disease
[29,30]. The neuropathology of AD shows a robust innate
immune response characterized by the presence of acti-
vated microglia, with increased or de novo expression
of diverse macrophage antigens [21], and at least in
some cases production of inflammatory cytokines [29,31].
It has been suggested that non-steroidal anti-inflammatory
drugs protect from the onset or progression of AD [32],
suggesting that inflammation is a causal component of the
disease rather than a consequence of the neurodegenera-
tion. Recent GWASs have highlighted several genes in-
volved in innate immunity, indicating also a causal role for
inflammation in the disease [33]. Additionally, a solid body
of evidence shows that systemic inflammation may interact
with the innate immune response in the brain to act as a
‘driver’ of disease progression and exacerbate symptoms
[7]. The impact of systemic inflammation on the progres-
sion of AD means that any neuropathology study on the
inflammatory response in the AD brain must take into
account systemic co-morbidities that may influence the
microglia phenotype (see ‘Information required for the
analysis of the immune response in Alzheimer’s disease’
section).
The definition of the brain inflammatory profile of AD
shows conflicting ideas in the literature, probably arising
from the heterogeneity of the post-mortem samples and
the difficult application of the detection methods [21].
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type, characterized by expression of interleukin-1 beta
(IL-1β) and complement proteins [34,35]. The upregula-
tion of genes linked to an anti-inflammatory phenotype,
arginase 1, or the transforming growth factor-beta (TGF-β)
has also been reported in association with AD [36,37]. The
consensus defines that, in the human AD brain, the inflam-
matory response cannot be classified as strictly M1-like
or M2-like [38] and that the changes in expression level
are compounded by the various detection methods (for
review, see [29]).
Although the precise inflammatory phenotype of micro-
glia in AD seems elusive, the link of AD with inflamma-
tion seems clear, as highlighted by a recent study using
microarray technology on the gene signature of ageing
and AD [39]. These ideas support the model of an activa-
tion of the innate inflammatory response in microglia as a
prelude to the development of AD [39]. Furthermore,
studies on incipient AD samples show a strong correlation
of genes associated with the microglial response and the
progression into AD [40]. The concept of the interconnec-
tion of AD and the innate immune response is supported
by evidence from a GWAS implicating genes involved in
innate immunity [41]. These promising studies are open-
ing new avenues into the understanding of the impact of
the innate immune response in AD while supporting the
need for future exploration.
Characterising the inflammatory response in human
post-mortem AD samples by using reliable and consistent
methods will provide valuable information in the field. It
could be agreed that analysing the expression of inflam-
matory mediators at the protein level, rather than the
analysis of the mRNA expression, is highly desirable.
To accomplish this task, the market offers a number of
multiplex systems to analyse several molecules simul-
taneously, accelerating research and minimising costs.
It is highly encouraged to analyse a broad range of
inflammatory mediators instead of using a limited number
of molecules as a proxy. New technical progress aimed at
increasing the panel of molecules to be analysed, as well
as the detection levels, will provide a valuable approach to
be able to trace comparisons like those recently used to
define the microglial gene signature in mice [42,43].
Phagocytosis
The phagocytic ability of microglia is a feature shared with
peripheral macrophages, helping to eliminate bacterial,
necrotic, or apoptotic cells during development or disease.
In AD, the amyloid plaque burden increases with age in
both mouse models [44] and human patients [45], indi-
cating the rather ineffective phagocytic potential of
microglia. Amyloid-beta (Aβ) deposits have been shown
to have a potent chemoattractant activity on microglia,
although their removal by phagocytosis has not beenclearly evidenced in vivo [46]. However, it has been shown
that the removal of Aβ can be improved by further chal-
lenge of microglia with high doses of lipopolysaccharide
[47] or the induction of IL-1β [48]. In human AD, active
immunotherapy directed against Aβ has been successful
in Aβ removal, partly by redirecting the microglia to-
ward Aβ [23] and by increasing their phagocytic activity
[49]. Recent evidence supports a differential contribu-
tion of perivascular macrophages and parenchymal micro-
glia, not bone marrow-derived cells, to the clearance of
Aβ [50]. In this study, the authors used mice deficient in
CCR2, a molecule expressed by monocytes defining
their migration, to rule out the contribution of circulating
monocytes, further evidencing a prominent role of the
perivascular macrophage population to Aβ clearance [50].
Interestingly, as microglia do not express CCR2 in healthy
and diseased conditions [51,52], the analysis of this
molecule in comparison with other markers expressed
by microglia (that is, CX3CR1) can help to potentially dif-
ferentiate the infiltrated monocytes/macrophages from
the resident microglia. This comparison has not been
performed yet in the human brain and would provide
valuable insights for the understanding of the balance
of microglia/macrophages.
The regulation of the phagocytic activity of microglia
appears as a key genetic determinant of AD pathology.
Recent studies link genetic variants of TREM2, a protein
regulating the activation and phagocytic functions of myeloid
cells, with the risk of developing AD [53,54]. TREM2 has a
balancing role between phagocytic and pro-inflammatory
microglial activities and is expressed in microglia around
plaques in an experimental model of AD [55]. Similarly,
dysregulation of the complement system in humans has
been associated with AD [18]. However, no clear consen-
sus defines the overall level of microglial phagocytosis in
the human AD brain. The use of refined experimental ap-
proaches to directly study microglial phagocytosis [56], to-
gether with the analysis of immunological markers such as
CD68 (related with phagocytic activity), will shed light on
the understanding of the phagocytic activity of microglia
and other macrophage populations in the AD brain.Proliferation
Microglial activation in neurodegeneration is accompan-
ied by an increase in their numbers. The contribution of
circulating progenitors to the microglial population is
minor, or even absent, as shown in a mouse model of AD
[50], pointing to in situ microglial proliferation as the
mechanism regulating microglial turnover [57]. In mice,
microglia are maintained and function largely independ-
ently of circulating progenitors in health [58,59] and
disease [50,52,60]. Therefore, the analysis of microglial
proliferation in AD is necessary for understanding how
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onset or progression or both.
Proliferation was assumed to be responsible for the in-
creased number of microglial cells observed in AD sam-
ples, although direct evidence of proliferating microglial
cells (that is, Ki67 expression in Iba1+ cells) was reported
only recently [60]. The expansion of the microglial popu-
lation has been consistently documented in transgenic
mouse models of AD, mainly accumulating around pla-
ques [61]. However, direct evidence of microglial prolifera-
tion (incorporation of 5-bromo-2-deoxyuridine in Iba1+
cells) was only recently reported, suggesting a direct effect
of the plaque microenvironment over the regulation of
microglial proliferation [62]. These studies pinpoint the
importance of the control of microglial proliferation dur-
ing AD. Establishing reproducible and consistent methods
to monitor microglial proliferation in post-mortem AD
brains will provide the scientific community with valuable
tools to better compare results across cohorts of patients,
contributing to our better understanding of the patho-
physiology of AD [63].
The analysis of microglial proliferation is best achieved
by double/triple immunohistochemical analysis by using ei-
ther fluorescence or bright-field microscopy [63] (Figure 1).
The use of fluorescence-based techniques needs to be
supplemented by the use of a fluorescence-quenching
step (for example, Sudan Black). This step is particularly
important in the case of AD human tissue, as the occur-
rence of autofluorescent artefacts (for example, lipofuscin
granules) is very frequent and can compound the interpret-
ation of results. Double bright-field immunohistochemistryFigure 1 Microglial proliferation in post-mortem human Alzheimer’s
microglial cells (Iba1+) by bright-field double immunohistochemistry (A)
(B) (Alexa 568, red, Iba1; Alexa 488, green, Ki67) from the temporal cortex
Iba1, ionized calcium-binding adaptor molecule 1.can be achieved by combining DAB and alkaline phosphat-
ase reactions, labelling two individual antibodies with a
brown or blue precipitate, respectively. Both fluorescent
and bright-field microscopy methods need to implement a
membrane or cytoplasmic microglial marker (Iba1, CD68,
and CD11b) and a nuclear proliferation marker (Ki67,
phospho-histone H3, and PCNA), together with nuclear
counterstaining to decipher the subcellular localization
of the proliferation markers. The analysis of double- or
triple-staining techniques needs to be coupled to colour
deconvolution methods.Cell infiltration
Cell infiltration in the brain during AD is an import-
ant question related to the potential roles for recruited
monocytes/macrophages and T cells within the brain
parenchyma. Infiltration of peripheral leukocytes in the
human AD brain is very limited when compared with
classic autoimmune diseases like multiple sclerosis [64].
However, the rare coincidence of stroke and AD leads to
an increase in infiltrating macrophages in the brain, which
contained Aβ fibrils suggesting an effective plaque clear-
ance response [65]. Although limited evidence is available
in the literature regarding the existence and role of infil-
trated leukocytes in human AD, these studies suggest that
systemic co-morbidities could determine the degree of in-
filtration of circulating leukocytes. It should be noted that
the findings on analysis of post-mortem tissue several years
following any event which might impact on neuroin-
flammation (insult, trauma, disease, treatment) may notdisease brain. Representative images of the detection of Ki67 in
(DAB, brown, Iba1; AP, blue, Ki67) or double immunofluorescence
of a patient with Alzheimer’s disease. Images adapted from [63].
Table 1 Analysis of immune changes in human post-mortem
tissue
Human post-mortem
tissue
- Genetic heterogeneity
- Age and gender
- Agonal status
- Co-morbidities
- Cause of death
- Post-mortem interval
Techniques
Fixed tissue - Immunohistochemistry
○ Bright-field microscopy [23,49,60]
○ Fluorescent microscopy [23,49,60]
○ Combination of different markers [23,49,60]
Frozen tissue - Genomics [39]
- Proteomics [74]
- RNA/DNA analysis [38,75,76]
- Primary culture [73]
- Flow cytometry [73]
Assessment
Qualitative - Cell type
- Cell morphology
Quantitative - Semi-quantitative rating system
- Number of cells per area or volume unit
- Protein load (percentage)
Immune functions
Inflammatory
profile
- Pro- versus anti-inflammatory cytokines
- CD14, CD40, major histocompatibility complex II,
arginase 1, chitinase, and TREM2
Phagocytosis - Scavenger receptors (CD68 and CD36), TREM2,
FcγRs CD14/TLR4, and phosphatidylserine
receptors
Proliferation - Ki67, PCNA, and phospho-histone H3
Immune cell
infiltration
- Monocytes
○ CCR2 combined with CX3CR1
○ CD45, LyC6, and CD11c
- T cells
○ CD4 (T helper)
○ CD8 (T cytotoxic/suppressor)
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and instead represent the later effects.
As explained before (in the ‘Proliferation’ section), ex-
periments in mouse models of AD suggest that the infil-
tration of circulating monocytes is scarce and does not
contribute to the pool of parenchymal microglia [52].
Translating these findings to the human situation is a
challenging task because of the lack of specific markers
to distinguish microglia from peripheral leukocytes, al-
though the analysis of the levels of molecules like CD45,
Ly6C, or CD11c could help to split the contribution
from both populations [66].
The study of the adaptive immune response in AD has
provided valuable information in the last few years. T-cell
number—both the CD4+ (T helper) and the CD8+ (T
cytotoxic/suppressor) populations—increases in patients
with AD [67]. Although the number of T cells is higher in
AD brains, they do not express markers of proliferation,
indicating an absence of antigen-triggered clonal expan-
sion [67]. However, there is evidence indicating the or-
chestration of a systemic T-cell response, as suggested by
the presence of the RO isoform of CD45 in peripheral T
cells in patients with AD, linked to T-cell memory [68],
and by the increase in the CD4+ and CD25+ regulatory
subsets in patients with AD [69]. However, the role of the
T cells infiltrated in the brains of patients with AD is un-
clear. Major histocompatibility complex class II is found
upregulated in microglia surrounding Aβ plaques in the
AD brain, indicating possible antigen presentation [30].
However, the co-stimulatory factors CD80 and CD86 are
required for the induction of primary adaptive immune re-
sponses and their description in microglia in AD remains
elusive [70]. Infiltration of T lymphocytes has been associ-
ated with the development of side effects in a number of
AD patients immunised against Aβ [71,72]. However,
analysis of T cells in a cohort of immunised AD cases
compared with unimmunised AD cases did not show a
difference [23]. Therefore, a detailed analysis of the T
cell-dependent responses in the brain parenchyma is
required to fully understand the role of these cells in
AD pathology. The use of fresh samples, allowing flow
cytometry analysis and cell culture [73], would provide
the optimal tool to overcome the limitations of using
post-mortem tissue for this purpose.
Conclusions
A number of recent publications have highlighted specific
inflammatory profiles associated with healthy or diseased
brain [38,39]. However, our current knowledge of the
neuroinflammatory response in AD is based mainly on
in vitro and animal studies. Therefore, it is essential to
confirm or contradict the experimental findings in the
human brain in order to increase our knowledge of the
pathogenic mechanisms of AD. This strategy wouldlead to the identification of potential therapeutic tar-
gets without undermining the benefit of animal models.
The recent development of brain banks with the aim of
providing good-quality tissue for research, in associ-
ation with the tools now available to identify genes and
proteins (Table 1), should soon increase our under-
standing of the role of immunity in neurodegenerative
diseases.
Note: This article is part of a series on Innate Immunity, edited
by Donna Wilcock. Other articles in this series can be found at
http://alres.com/series/innateimmunity.
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